Japanese drugmaker Daiichi Sankyo said Tuesday it lost 335.8 billion yen (3.45 billion dollars) in the year to March because of a plunge in the value of its investment in India’s Ranbaxy Laboratories.
It booked a loss of 351.3 billion yen on the Ranbaxy shares, which have fallen more than two-thirds since June when Daiichi announced it would buy 64% of India’s top generic drugmaker for up to 4.6 billion dollars.
The previous year Daiichi, Japan’s third largest drugmaker, had logged a net profit of 97.66 billion yen.
Ranbaxy shares have slumped due to weak global markets, financial losses reported by the Indian company and regulatory setbacks in the United States, the world’s biggest drug market.
Ranbaxy, which derives 80% of its sales from abroad, has grown by selling cheap copies of branded drugs that have gone off-patent and through successful challenges to patents owned by Western companies.
But the US Food and Drug Administration (FDA) last September banned imports of more than 30 generic drugs produced by Ranbaxy because of problems in their production at two plants in India.
“If the resolution of this issue were to become protracted or the FDA imposed additional restrictions on Ranbaxy, this could have a severe impact on Ranbaxy’s business prospects in the US market,” Daiichi warned in a statement.
The Japanese company expects to return to the black in the current business year to March with a net profit of 40 billion yen.
But it said the global market environment would remain harsh due to the economic downturn and government restrictions on medical spending.
Leave Your Comment
9 years ago
Japan’s third-largest drugmaker, Daiichi Sankyo Co, said on Monday it...
2 years ago
Japan’s Daiichi Sankyo Co Ltd said on Friday brothers Malvinder Mohan Singh...
10 years ago
Ranbaxy Pharmaceuticals has said that the ongoing investigations by US...